T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$2.03B |
| 2 |
Rockwell Automation
ROK
|
+$1.44B |
| 3 |
Autodesk
ADSK
|
+$1.15B |
| 4 |
Citigroup
C
|
+$975M |
| 5 |
ConocoPhillips
COP
|
+$967M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.59B |
| 2 |
GE Aerospace
GE
|
+$1.78B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.38B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 5 |
Philip Morris
PM
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.21% |
| 2 | Healthcare | 15.42% |
| 3 | Financials | 10.99% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
RUM Group Inc
RUM
$3.82B
| $111K | ﹤0.01% |
13,700
| – | – |
|
2752
Akebia Therapeutics
AKBA
$247M
| $110K | ﹤0.01% |
59,900
| – | – |
|
2753
Advantage Solutions
ADV
$412M
| $109K | ﹤0.01% |
1,000
+183
| +22% | +$18K |
|
2754
Daktronics
DAKT
$987M
| $109K | ﹤0.01% |
+10,923
| New | +$91.1K |
|
2755
Definitive Healthcare
DH
$67.6M
| $109K | ﹤0.01% |
13,391
+1,387
| +12% | +$12.3K |
|
|
INZY
2756
DELISTED
Inozyme Pharma
INZY
| $109K | ﹤0.01% |
14,222
+1,526
| +12% | +$8.37K |
|
|
OSG
2757
DELISTED
Overseas Shipholding Group Inc.
OSG
| $109K | ﹤0.01% |
17,020
+1,162
| +7% | +$6.93K |
|
2758
Comtech Telecommunications
CMTL
$51.8M
| $107K | ﹤0.01% |
30,997
+2,042
| +7% | +$12.8K |
|
|
RPC
2759
Ridgepost Capital
RPC
$979M
| $107K | ﹤0.01% |
12,608
+1,747
| +16% | +$15.3K |
|
|
FARM
2760
DELISTED
Farmer Brothers
FARM
| $106K | ﹤0.01% |
29,600
| – | – |
|
2761
MaxCyte
MXCT
$161M
| $106K | ﹤0.01% |
25,199
+4,320
| +21% | +$20.3K |
|
2762
NuScale Power
SMR
$3.99B
| $106K | ﹤0.01% |
19,729
+4,014
| +26% | +$14.4K |
|
2763
Purple Innovation
PRPL
$29.2M
| $105K | ﹤0.01% |
2,400
+816
| +52% | +$27.2K |
|
2764
Vuzix
VUZI
$219M
| $105K | ﹤0.01% |
86,380
-3,710
| -4% | -$6.05K |
|
2765
Petco
WOOF
$814M
| $104K | ﹤0.01% |
45,290
+4,836
| +12% | +$12.3K |
|
2766
Applied Digital
APLD
$8.87B
| $103K | ﹤0.01% |
24,018
+3,182
| +15% | +$16.1K |
|
|
VXRT
2767
DELISTED
Vaxart
VXRT
| $103K | ﹤0.01% |
78,500
| – | – |
|
2768
Fossil Group
FOSL
$326M
| $102K | ﹤0.01% |
99,488
+49,100
| +97% | +$54.8K |
|
2769
GoodRx Holdings
GDRX
$1.23B
| $102K | ﹤0.01% |
14,300
| – | – |
|
2770
Innodata
INOD
$1.99B
| $102K | ﹤0.01% |
15,348
+982
| +7% | +$8.16K |
|
2771
Sutro Biopharma
STRO
$358M
| $102K | ﹤0.01% |
1,803
+358
| +25% | +$15.8K |
|
2772
Tango Therapeutics
TNGX
$4.35B
| $102K | ﹤0.01% |
12,771
+1,426
| +13% | +$15.3K |
|
|
ENFN
2773
DELISTED
Enfusion, Inc.
ENFN
| $102K | ﹤0.01% |
+11,013
| New | +$96.9K |
|
|
TPIC
2774
DELISTED
TPI Composites
TPIC
| $100K | ﹤0.01% |
34,347
+3,737
| +12% | +$11K |
|
|
NXDR
2775
Nextdoor Holdings
NXDR
$998M
| $99K | ﹤0.01% |
43,779
+9,689
| +28% | +$18.1K |
|
Similar funds
T. Rowe Price Associates's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Associates held 3,021 positions worth $816B, up 9.6% from $744B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2024 filing shows 108 new, 1,941 increased, 738 reduced and 64 closed positions. Its largest new stake was GE Vernova: 2,687,194 shares worth $367M. The largest sale was NVIDIA, an estimated $2.59B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2024 buy was GE Vernova: 2,687,194 shares worth $367M.
- T. Rowe Price Associates added most to Fortinet in Q1 2024, an estimated $2.03B increase.
- T. Rowe Price Associates's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $2.59B.
- T. Rowe Price Associates fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $621M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $816B portfolio in Q1 2024.
- T. Rowe Price Associates opened 108 new positions and closed 64 in Q1 2024.
- T. Rowe Price Associates's portfolio value rose 9.6% quarter-over-quarter to $816B.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.